HC Wainwright Has Positive Estimate for CorMedix Q3 Earnings

Key Points

• HC Wainwright has raised its Q3 2025 earnings per share estimate for CorMedix to $0.43, up from $0.33, and maintains a "Buy" rating with a price target of $17.00.
• CorMedix reported Q2 earnings of $0.28 EPS, exceeding expectations and marking a significant revenue increase of 4830.1% compared to the same quarter last year.
• Insiders have sold over 163,997 shares of CorMedix stock in the past three months amidst fluctuating ratings and price targets by various analysts.

CorMedix Inc (NASDAQ:CRMD - Free Report) - Analysts at HC Wainwright increased their Q3 2025 earnings per share estimates for shares of CorMedix in a report released on Thursday, September 25th. HC Wainwright analyst B. Folkes now anticipates that the company will earn $0.43 per share for the quarter, up from their previous estimate of $0.33. HC Wainwright currently has a "Buy" rating and a $17.00 price target on the stock. The consensus estimate for CorMedix's current full-year earnings is ($0.32) per share. HC Wainwright also issued estimates for CorMedix's FY2027 earnings at $2.17 EPS and FY2029 earnings at $2.67 EPS.

CorMedix (NASDAQ:CRMD - Get Free Report) last announced its quarterly earnings results on Thursday, August 7th. The company reported $0.28 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.20 by $0.08. CorMedix had a net margin of 42.11% and a return on equity of 42.73%. The company had revenue of $39.74 million during the quarter, compared to the consensus estimate of $29.88 million. During the same quarter in the previous year, the company posted ($0.25) earnings per share. The company's revenue for the quarter was up 4830.1% compared to the same quarter last year.

A number of other equities analysts have also recently issued reports on the company. D Boral Capital cut CorMedix from a "strong-buy" rating to a "hold" rating in a report on Monday, June 30th. Wall Street Zen upgraded shares of CorMedix from a "buy" rating to a "strong-buy" rating in a research note on Saturday, September 13th. JMP Securities reissued a "market outperform" rating and set a $22.00 target price on shares of CorMedix in a research note on Tuesday, September 9th. D. Boral Capital downgraded CorMedix from a "buy" rating to a "hold" rating in a research note on Monday, June 30th. Finally, Royal Bank Of Canada raised CorMedix from an "outperform" rating to a "moderate buy" rating and upped their target price for the stock from $13.00 to $17.00 in a research report on Friday, June 20th. One equities research analyst has rated the stock with a Strong Buy rating, five have given a Buy rating and two have issued a Hold rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and an average price target of $18.00.

CorMedix Stock Performance

Shares of CRMD stock opened at $11.12 on Friday. The business's fifty day moving average is $12.34 and its 200-day moving average is $11.30. The stock has a market cap of $868.03 million, a PE ratio of 14.83 and a beta of 1.76. CorMedix has a 1 year low of $5.60 and a 1 year high of $17.43.

Institutional Investors Weigh In On CorMedix

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Canada Pension Plan Investment Board acquired a new position in CorMedix during the second quarter valued at approximately $42,000. USA Financial Formulas acquired a new stake in shares of CorMedix in the second quarter worth $55,000. Russell Investments Group Ltd. boosted its holdings in shares of CorMedix by 22.2% during the 2nd quarter. Russell Investments Group Ltd. now owns 6,553 shares of the company's stock worth $81,000 after buying an additional 1,190 shares during the period. Ameritas Investment Partners Inc. grew its stake in CorMedix by 17.9% in the 2nd quarter. Ameritas Investment Partners Inc. now owns 6,562 shares of the company's stock valued at $81,000 after buying an additional 998 shares during the last quarter. Finally, NewEdge Advisors LLC acquired a new position in CorMedix in the 2nd quarter valued at $92,000. 34.18% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling at CorMedix

In other CorMedix news, Director Alan W. Dunton sold 10,000 shares of the stock in a transaction on Friday, September 12th. The shares were sold at an average price of $13.13, for a total transaction of $131,300.00. Following the transaction, the director directly owned 40,250 shares of the company's stock, valued at $528,482.50. This represents a 19.90% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, insider Kaufman Beth Zelnick sold 50,000 shares of the firm's stock in a transaction dated Tuesday, September 9th. The shares were sold at an average price of $13.41, for a total value of $670,500.00. Following the transaction, the insider owned 180,418 shares in the company, valued at approximately $2,419,405.38. This trade represents a 21.70% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders have sold 163,997 shares of company stock valued at $2,163,617. Company insiders own 5.30% of the company's stock.

CorMedix Company Profile

CorMedix Inc, a biopharmaceutical company, focuses on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory diseases in the United States. Its lead product candidate is DefenCath, an antimicrobial catheter lock solution to reduce the incidence of catheter-related bloodstream infections in adult patients with kidney failure.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.